Lynsight

Lynsight Improving outcomes through reliable Lynch syndrome diagnostics and raising cancer risk awareness.

Early prevention starts with a conversation. Talking openly with your family about your diagnosis can empower loved ones...
02/12/2025

Early prevention starts with a conversation.

Talking openly with your family about your diagnosis can empower loved ones to take charge of their health. Together, you can take proactive steps to protect future generations.

Don’t wait. Learn more about Lynch syndrome testing for you and your family: https://lynsightlabs.com/lynch-syndrome-testing/

This Thanksgiving, we’re grateful for our dedicated team, our research partners, and everyone working to advance underst...
27/11/2025

This Thanksgiving, we’re grateful for our dedicated team, our research partners, and everyone working to advance understanding and care for those affected by Lynch syndrome. From all of us at Lynsight, thank you for being part of our journey toward a healthier future.

Wishing you a wonderful holiday filled with gratitude, connection, and hope.

Lynch syndrome is one of the most common hereditary cancer syndromes, yet too often it goes undiagnosed until a serious ...
25/11/2025

Lynch syndrome is one of the most common hereditary cancer syndromes, yet too often it goes undiagnosed until a serious health issue emerges.

A growing body of research, including recent findings published in Clinical Gastroenterology and Hepatology, makes a strong case for universal Lynch syndrome screening. This proactive approach could lead to earlier detection, better outcomes, and lasting benefits for patients, families, and healthcare systems alike.

Read the full blog to learn why now is the time to make universal screening the standard: https://lynsightlabs.com/why-universal-lynch-syndrome-screening-matters/

At Lynsight, we recognize World Pancreatic Cancer Day as a vital opportunity to raise awareness, promote early detection...
20/11/2025

At Lynsight, we recognize World Pancreatic Cancer Day as a vital opportunity to raise awareness, promote early detection, and stand in solidarity with those affected by this disease.

Pancreatic cancer is one of the most aggressive cancers, with genetics playing a significant role in some cases, including those related to Lynch syndrome. Early detection can make all the difference, which is why awareness and education are so critical.

Whether you're honoring a loved one, raising awareness, or advancing research, your voice matters. Together, we can make early detection and better outcomes possible.

See how Lynsight is leading the way in early cancer detection: https://lynsightlabs.com/lynch-syndrome-testing/

On September 30, came together for our Fall Quarterly Meeting at the stunning Haikko Manor in Porvoo, Finland. Surroun...
19/11/2025

On September 30, came together for our Fall Quarterly Meeting at the stunning Haikko Manor in Porvoo, Finland. Surrounded by history and inspiration, we reconnected, reflected, and recharged our mission to advance Lynch syndrome research and innovation.

We’re excited for what’s ahead! Follow our journey as we continue driving discovery and impact for Lynch sydrome! 🧡

Read more about our impactful team meeting: https://lynsightlabs.com/lynsights-fall-quarterly-meeting-a-memorable-blend-of-insight-and-team-spirit-at-haikko-manor/

What an unforgettable few days! The 2025 -GGC Annual Meeting marked a major milestone: 30 years of progress, collaborati...
13/11/2025

What an unforgettable few days! The 2025 -GGC Annual Meeting marked a major milestone: 30 years of progress, collaboration, and innovation in the fight against hereditary GI cancer syndromes.

Since 1995, CGA-IGC has built a global community of clinicians, researchers, and advocates dedicated to advancing prevention, diagnosis, and treatment. This year, that spirit was stronger than ever, as we gathered in St. Louis to reflect on our shared history and look boldly toward the future of care.

Thank you to everyone who participated, presented, and contributed to this incredible event. Together, we’re shaping the next chapter in hereditary GI cancer research and care.

If you missed the event, visit our site to learn more about Lynch sydrome testing: https://lynsightlabs.com/lynch-syndrome-testing/

12/11/2025

Clarity starts here. At Lynsight, we give you answers, not maybes. Take control of your health with straightforward, reliable testing for Lynch syndrome.

Your future shouldn't be a question mark. Ask Lynsight: https://lynsightlabs.com/

🚨 Last call! Do you want to help raise Lynch syndrome awareness and advance life-saving testing? Here’s your chance to s...
10/11/2025

🚨 Last call!

Do you want to help raise Lynch syndrome awareness and advance life-saving testing? Here’s your chance to support the transformation of hereditary cancer diagnostics.

Our patented DiagMMR technology is a true breakthrough: a tumor-independent test capable of detecting Lynch syndrome, the most common hereditary cancer syndrome, before cancer develops. With 94% accuracy demonstrated in Finland, DiagMMR is now on a clear path toward FDA regulatory approval, with U.S. commercialization planned for early 2027.

Help us make early detection accessible for everyone.

Invest today in the future of Lynch syndrome testing:
https://www.invesdor.com/rounds/1138a782-88f7-44bf-8874-fedc8c49a374 #/

New Day Diagnostics

We’re proud to announce our strategic partnership with New Day Diagnostics, a leading innovator in diagnostic solutions,...
06/11/2025

We’re proud to announce our strategic partnership with New Day Diagnostics, a leading innovator in diagnostic solutions, to initiate clinical studies and accelerate U.S. market access for DiagMMR, our proprietary diagnostic test for identifying mismatch repair deficiencies, the key biomarker in Lynch syndrome.

This milestone marks a major step in our mission to expand access to advanced diagnostics and improve early detection of hereditary cancer syndromes. Together, we’re combining clinical validation, research infrastructure, and shared expertise to bring DiagMMR to healthcare providers and patients across the U.S.

Clinical studies are set to begin in early 2026 with top-tier U.S. institutions, paving the way for FDA authorization and nationwide impact.

Read the full press release to learn more about the partnership: https://lynsightlabs.com/lynsight-announces-strategic-partnership-with-new-day-diagnostics-to-advance-diagmmr-clinical-studies-in-the-united-states/

Early detection saves lives.Lynch syndrome is one of the most common inherited conditions, and often goes undiagnosed.By...
04/11/2025

Early detection saves lives.

Lynch syndrome is one of the most common inherited conditions, and often goes undiagnosed.

By prioritizing preventative health and genetic testing, we can identify risk early and take action before cancer develops.

Learn more about the impact of Lynch syndrome testing → https://lynsightlabs.com/lynch-syndrome-testing/

Exciting news from Lynsight!We’re excited to announce that Lynsight has officially opened its public investment round, o...
31/10/2025

Exciting news from Lynsight!

We’re excited to announce that Lynsight has officially opened its public investment round, offering a chance to join a company that is redefining hereditary cancer diagnostics. Our patented DiagMMR technology represents a true breakthrough: a tumor-independent test that can detect Lynch syndrome, the most common hereditary cancer syndrome, before cancer develops. With 94% accuracy demonstrated in Finland, DiagMMR is now on a clear path toward FDA regulatory approval, with U.S. commercialization planned for early 2027.

Join us in making early detection accessible for all. 💙

Invest in the future of Lynch sydrome testing: https://www.invesdor.com/rounds/1138a782-88f7-44bf-8874-fedc8c49a374 #/

Osoite

ArabianKatu 12
Helsinki
00560

Aukioloajat

Maanantai 09:00 - 17:00
Tiistai 09:00 - 17:00
Keskiviikko 09:00 - 17:00
Torstai 09:00 - 17:00
Perjantai 09:00 - 17:00

Puhelin

+358406602622

Nettisivu

Hälytykset

Tiedä ensimmäisenä ja anna meille oikeus lähettää sinulle sähköpostitse uutisia ja promootioita Lynsight :ltä. Sähköpostiosoitettasi ei käytetä muihin tarkoituksiin, ja voit perua milloin tahansa.

Oikopolut

Jaa

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Kategoria